Dermatologic symptoms associated with the multikinase inhibitor sorafenib

Background The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms. Objective We sought to evaluate and provide guidance on the diagnosis and clinical management of dermatologic symptoms associated with sorafenib in patients with advanced...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2009-02, Vol.60 (2), p.299-305
Main Authors: Robert, Caroline, MD, PhD, Mateus, Christina, MD, Spatz, Alain, MD, Wechsler, Janine, MD, Escudier, Bernard, MD
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Benzenesulfonates - administration & dosage
Benzenesulfonates - adverse effects
Biological and medical sciences
Dermatology
Humans
Medical sciences
Neoplasms - drug therapy
Niacinamide - analogs & derivatives
Phenylurea Compounds
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Pyridines - administration & dosage
Pyridines - adverse effects
Skin Diseases - chemically induced
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms. Objective We sought to evaluate and provide guidance on the diagnosis and clinical management of dermatologic symptoms associated with sorafenib in patients with advanced solid tumors. Methods English-language studies representative of a patient population with a variety of tumor types, who received single-agent sorafenib, were selected. Particular emphasis was placed on the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGETs). Results Frequently observed dermatologic side effects (any grade in TARGETs) of sorafenib include rash/desquamation (40%), hand–foot skin reaction (30%), alopecia (27%), and pruritus (19%). Generally, dermatologic symptoms resolve with appropriate management, including topical treatments, dose interruptions, dose reductions, or a combination of these. Limitations The results presented here are based on a limited number of studies. Conclusion Although sorafenib is associated with dermatologic symptoms, these are usually resolved with appropriate intervention, patient-led practical treatment, and preventative measures.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2008.06.034